Osteogenesis
Introduction
Ectopic ossification in skeletal muscle is characteristic of certain muscle diseases in humans (Kocyigit et al., 2001; Mahboubi et al., 2001) . Bone marrow stromal cells are thought to be the primary source of osteoprogenitor cells in the body. Although intravenously transplanted mouse bone marrow cells settle in skeletal muscles (Brazelton et al., 2003; Ferrari 0925-4773/$ -see front matter Ó 2007 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.mod.2007.11. 004 et al., 1998; LaBarge and Blau, 2002) , these cells have not been shown to migrate to muscle during ectopic ossification. Previous studies have suggested that osteoprogenitor cells reside in skeletal muscle, although their source has remained unknown (Bosch et al., 2000; Levy et al., 2001) . Recent studies, however, suggest that vascular smooth muscle cells are candidates for osteoprogenitors in human skeletal muscle (Hegyi et al., 2003; Levy et al., 2001) .
Muscle satellite cells are skeletal muscle stem cells that are activated to proliferate and then fuse with each other to form myofibers during muscle regeneration. Histopathologic and molecular biological studies indicate that progenitor cells derived from muscle satellite cells differentiate exclusively into myotubes and myofibers in vivo. However, our clonal analysis demonstrated that mouse muscle satellite cells actually preserve the ability to undergo osteogenic terminal differentiation in vitro in a bone morphogenetic protein (BMP) stimulation-dependent manner (Wada et al., 2002) . Our previous results also suggest the possibility that failure of the restriction of phenotypic plasticity triggers ectopic ossification in muscle satellite cells (Wada et al., 2002) .
A previous study referred to bone marrow stromal cells, which form bone spontaneously, as ''determined osteoprogenitor cells'' and to osteoprogenitor cells from extraskeletal sources, which require inductive agents to express osteogenic phenotypes, as ''inducible osteoprogenitor cells '' (Friedenstein and Kuralesova, 1971) . In mice, descendants of muscle satellite cell undergo osteogenic differentiation only when exposed to BMPs in vitro (Asakura et al., 2001; Hashimoto et al., 2004; Wada et al., 2002) . In the absence of BMPs, these cells preferentially undergo myogenic terminal differentiation in vitro. However, it remains to be determined whether osteogenic differentiation of human myogenic cells depends on BMP stimulation, although our previous study demonstrated that these cells are able to undergo osteogenic terminal differentiation in vitro (Wada et al., 2002) . In addition, the involvement of BMPs in ectopic bone formation in skeletal muscle has not been shown in human disorders. Therefore, it is likely that ectopic bone formation in human skeletal muscle can be triggered in a BMP-independent manner, although ''determined osteoprogenitor cells'' have not been identified in human skeletal muscle.
We here show that muscle progenitor cells spontaneously expressed both a marker of muscle satellite cells and a marker of osteoblasts in regenerating human muscle. We then cultured both primary and immortalized human myogenic progenitor cells to determine whether they can undergo osteogenic differentiation without exogenous BMPs. We found that exogenous BMP stimulation is not necessary to induce ossification in both primary and immortalized human myogenic progenitor cells. Therefore, we propose the hypothesis that human myogenic progenitor cells preserve the ability to act as ''determined osteoprogenitor cells'' and undergo osteogenic terminal differentiation when myogenic differentiation is impaired in human muscle diseases. In addition, the immortalized human myogenic progenitor cell lines used have a multipotentiality that enables us to analyze the nature of human myogenic progenitor cells in detail, as previously done in mouse and rat myoblastic cell lines. They will also provide a model system for genetic modification and transplantation of human myogenic cells.
Results

Osteogenic properties of a human myogenic cell lineage in vivo
The transcription factor Pax7 is expressed exclusively in muscle satellite cells in mouse skeletal muscle (Seale et al., 2000) . To determine whether Pax7 is a specific marker for human muscle satellite cells, we probed cryosections prepared from normal back muscle with antibodies to this protein. Pax7-positive nuclei were detected exclusively between the basement membrane and the sarcolemma, which were recognized by antibodies to laminin and dystrophin, respectively (Fig. 1A) , suggesting that Pax7 is indeed specifically expressed in human muscle satellite cells (Reimann et al., 2004) . Quiescent muscle satellite cells expressing Pax7 did not express bone-specific alkaline phosphatase (ALP), an early marker of osteogenic differentiation. In contrast, ALP was detected histochemically in the small regenerating myofibers present in humans with skeletal muscle diseases including Duchenne muscular dystrophy (DMD) (Fig. 1B-D) (Nonaka et al., 1981) . To determine whether human myogenic progenitor cells express osteogenic markers during muscle regeneration, we examined the expression of ALP in muscle of individuals with DMD. In DMD muscles, muscle regeneration is spontaneously triggered and myogenic progenitor cells are present, although ectopic bone has not been found. Immunofluorescence analysis revealed that the ALP activity in small myofibers of a 5-month-old boy with DMD was attributable to bone-specific ALP located at the plasma membrane ( Fig. 1C and D) . Probing cryosections with antibodies to Pax7 and bone ALP also revealed several mononucleated cells coexpressing Pax7 and ALP in the regenerating muscle of a 4-month-old boy with DMD (Fig. 1B) . One or two double-positive cells were found in each cryosection ($20 mm 2 ) of muscles from these two boys with DMD. These results thus indicate that myogenic progenitor cells with both myoblastic and osteoblastic properties are present in regenerating human skeletal muscles in vivo. Pax7 expression suggests that these cells might be descendants of muscle satellite cells. The results suggest that human myogenic progenitors are probable candidates for osteoprogenitor cells.
2.2.
Coexpression of myoblast-and osteoblast-specific proteins in primary human myogenic progenitor cells in vitro
We previously isolated a primary human myogenic progenitor cell clone, Hu5, from the healthy subcutaneous muscle of a nondystrophic woman ( Fig. 2A) . To determine whether human muscle progenitor cells are able to act as osteoprogenitor cells, we characterized Hu5 cells. Expression of Pax7 was detected in the majority of Hu5 cells (more than 80%) in early passages (less than 6 passages), but not during successive passages (Fig. 2B) . Further, Hu5 cells differentiated spontaneously into prominent myotubes in vitro on achieving confluence (Fig. 2C) . They also underwent terminal osteogenic differentiation accompanied by calcification in the presence of both BMP2 and bGP, whereas myogenic differentiation is prevented (Hashimoto et al., 2006) . In addition, a phosphate donor, bGP, alone induced calcification in Hu5 cells without BMP2 stimulation (Fig. 2D) . Unexpectedly, ALP was detected histochemically in all unstimulated Hu5 cells (Fig. 2E ) whereas primary cultured mouse myogenic cells express bone ALP only when stimulated with BMP2 (Wada et al., 2002) . The observation is consistent with result that Hu5 cells underwent osteogenic terminal differentiation without BMP2 stimulation. Double staining revealed that more than 80% of undifferentiated Hu5 cells coexpressed Pax7 and bone ALP in the absence of BMP2 (Fig. 2F ) in a similar manner to mononucleated myogenic cells in vivo (Fig. 1E ). In addition, Hu5 cells also express determination genes, including those for MyoD and Runx2, which are specific for myogenic and osteogenic differentiation, respectively ( Table 2 ). The Hu5 cell, which is a myogenic progenitor cell clone derived from the healthy muscle, thus exhibits both myoblast-and osteoblast-specific properties. The expression of both myogenicand osteogenic-specific proteins was also demonstrated in six independent clones of myogenic progenitor cells isolated from the subcutaneous muscle of another woman (see Fig. S1 online). We found no clones that retain only myoblastor osteoblast-specific properties under our culture conditions. The results suggest that human myogenic progenitor cells coexpress myoblast-and osteoblast-specific proteins during in vitro culture.
2.3.
Preservation of dual lineage-specific properties in immortalized human myogenic progenitor cells
In contrast to primary cultured mouse myogenic cells, the primary myogenic progenitor cell clone Hu5 ceased proliferation and underwent replicative senescence after 10-12 passages. Hu5 cells also lost differentiation potential along with cellular senescence, making it difficult to characterize Hu5 cells undergoing replicative senescence. Therefore, to facilitate analysis of the myogenic and osteogenic properties of Hu5 cells at the molecular level, we used the cells that were immortalized in vitro by introduction of the reverse transcriptase component of human telomerase (hTert) and human papillomavirus (HPV)-16 E7 (Hashimoto et al., 2006) .
One of the Hu5-derived clones retaining myogenic differentiation potential, E18, was subjected to further analyses, although similar results were obtained with the other eight independent clones derived from individual Hu5 cells. The muscle lineage markers desmin, nestin, and a master gene for myogenesis, MyoD, were expressed in both parent Hu5 and immortalized E18 cells (Table 2 ).
In addition, Runx2 (Cbfa1), an essential transcription factor for osteogenesis (Komori et al., 1997; Otto et al., 1997) , and bone-specific ALP were expressed in both parent Hu5 and E18 cells (Table 2) . Taken together with the results here, the immortalized line E18 largely retains both the myoblastand osteoblast-specific properties that are preserved in the parent Hu5 cells.
E18 differentiated into myotubes under conditions that promote myogenic differentiation (Fig. 3A) , and MyoD was highly expressed in the nuclei of E18 myotubes (Fig. 3B ). The number of nuclei in myotubes was sometimes varied and mainly depended on cell density. E18 also underwent ossification when cultured in medium containing bGP alone (Fig. 3C ). Because the immortalized line E18 preserved both the properties and the multipotentiality that the parent Hu5 cells possess ( Fig. 2C and E) (Hashimoto et al., 2006) , we consequently studied the myogenic and osteogenic differentiation kinetics of E18.
Down-regulation of osteogenic properties during myogenesis in human myogenic progenitor cells
Culture of E18 under conditions that promote myogenic differentiation induced the expression of myogenic differentiation markers, including sarcomeric myosin heavy chain (MHC) and muscle creatine kinase (MCK), as well as the formation of myotubes ( Fig. 4Aa through d , and C). The MyoD protein level was reduced in undifferentiated E18 cells under low cell density culture conditions (Hashimoto et al., 2006) , but its expression was induced during myogenic differentiation culture ( Fig. 4Ae through h ); in contrast, parent Hu5 cells expressed MyoD throughout the culture ( Fig. 4Aq through t) . Although the level of MyoD expression in E18 cells under low cell density culture conditions was reduced, it is possible that the high level of expression of Myf5, another member of the MyoD family, compensated for the loss of MyoD function (Fig. 4C ). Both Hu5 and E18 cells were able to express MyoD and Runx2 simultaneously (Fig. 4An , q, and r). The expression of Runx2 at both the mRNA and protein levels decreased whereas the amount of myogenin mRNA increased during myogenic differentiation culture of both Hu5 and E18 cells ( Fig. 4Ai through l, q through t, and C). The expression of ALP was also down-regulated in terminally differentiated E18 myotubes (Fig. 4B ) as well as parent Hu5 myotubes (data not shown). Expression of the ectopic hTert and E7 genes persisted in E18 cells throughout myogenic terminal differentiation (Fig. 4C) . Together, these results thus indicate that expressions of both Runx2 and bone-specific ALP were downregulated in primary and immortalized human myogenic progenitor cells during myogenic differentiation. Hu5 cells (passage 6) were subjected to immunofluorescence analysis with antibodies to Pax7. (C) Primary Hu5 was grown to confluence in pmGM to trigger spontaneous differentiation into myotubes. The cells were then subjected to immunocytochemical analysis with antibodies to sarcomeric MHC (immune complexes were detected with the peroxidase substrate TrueBlue). (D) Primary Hu5 cells were cultured for 6 days in medium containing serum (10%) and bGP (10 mM), after which calcium deposition was detected by staining with Alizarin Red S. The cells were then examined by phase-contrast microscopy. (E) Undifferentiated Hu5 cells were subjected to immunohistochemical detection of ALP. Nuclei were stained with DAPI superimposed. (F) Undifferentiated Hu5 cells were subjected to immunofluorescence analysis with antibodies to Pax7 and to bone-specific ALP. Pax7 (green) was present in nuclei, whereas ALP (red) was localized to the plasma membrane. Scale bars: 20 lm (A, B, D, and F) and 50 lm (C and E). Expression of both myogenic and osteogenic lineage markers were determined by immunofluorescence analyses. a MyoD expression was up-regulated in a cell density-dependent manner (Hashimoto et al., 2006) .
Fig. 3 -Multipotentiality of an immortalized human myogenic progenitor cell clone E18. (A and B)
The Hu5-derived clone E18 differentiated into myotubes after culture for 6 days in pmDM. The cells were then subjected to immunofluorescence analysis with antibodies (red) to MHC in (A) or MyoD in (B). Nuclei were detected by staining with DAPI (blue) in (A). (C) E18 cells were cultured for 6 days in medium containing serum in the presence of BMP2 (500 ng/ml) plus bGP (10 mM). The cells were then stained with Alizarin Red S. Scale bar, 100 lm. 
2.5.
Osteogenic differentiation of human myogenic progenitor cells without BMP2-stimulation E18 cells expressed bone-specific ALP and were able to undergo osteogenic terminal differentiation in the absence of BMP2 (Figs. 3C, 4Ba) . To determine the role of BMP2 in the osteogenic differentiation of E18 cells, we cultured these cells in medium containing bGP, BMP2, or both for 6 days. Whereas bGP alone induced calcification in E18 as well as parent Hu5 cells (Figs. 2E, 3C ), BMP2 alone did not (Fig. 5A) ; BMP2 did, however, markedly enhance the effect of bGP during the early stage of osteogenic terminal differentiation (Fig. 5A) . BMP2 simultaneously inhibited myogenic differentiation (Fig. 5B  and C) . The enhancement of ossification by BMP2 was likely independent of its inhibition of myogenesis, given that bFGF inhibited myogenesis without enhancing ossification ( Fig. 5A and B) . In addition, exogenous BMP2 inhibited osteocalcin gene expression (Fig. 5B , lanes 4 and 6; also see Fig. S2 online). Osteocalcin is a late marker of osteogenic differentiation and inhibits ossification (Ducy et al., 1996) . Therefore, the results suggest that exogenous BMP2 enhances ossification in human myogenic progenitor cells through the inhibition of osteocalcin gene expression.
Expression of osteocalcin was induced in confluent E18 cells cultured in hDMEM supplemented with 10% FBS in the absence of BMP2 and bGP (Fig. 5B, lane 2) . The result shows that E18 cells retain the ability to undergo osteogenic differentiation spontaneously in vitro. Then, to determine whether human myogenic progenitor cells express BMPs by themselves, expression of BMPs was determined by RT-PCR analysis (Fig. 5D ). Both Hu5 and E18 cells expressed BMP4 but not BMP7. Hu5 cells also expressed BMP2 at trace levels, whereas E18 cells did not. In addition, both Hu5 and E18 cells also expressed another TGFb super-family member, myostatin. To determine whether the action of autocrined BMPs is required for maintenance of ALP expression, E18 cells were cultured in pmGM supplemented with a BMP inhibitor, noggin, for up to 3 days. However, even an excess of noggin did not inhibit ALP expression in E18 cells (Fig. 5E) . Thus, it is unlikely that expression of ALP in E18 cells depends on autocrined BMPs.
Whereas bGP alone markedly inhibited spontaneous myogenesis in confluent cultures of clone E18, the combination of bGP and BMP2 prevented it ( Fig. 5B and C) . Immunofluorescence analysis revealed that the number of MyoD-positive cells decreased, but that a substantial proportion of them remained after culture of E18 cells with bGP alone or with bGP plus BMP2 (Fig. 5C ). In contrast, the expression of MHC, which is encoded by a target gene of MyoD, was inhibited greatly by bGP alone and completely by both bGP and BMP2. These results suggest that MyoD expression is partially down-regulated during 6 days of culture but that MyoD function is almost completely suppressed during ossification induced by bGP. . Therefore, to explore the role of Rho signaling in the myogenesisosteogenesis switch of human myogenic progenitor cells, we examined the effects of modulating this pathway in either the myogenesis or osteogenesis of E18 cells. The amounts of both total and activated Rho proteins increased under myogenic differentiation-inducing conditions (Fig. 6A, left panels) . In contrast, total Rho protein levels remained constant and the amount of active Rho slightly declined during osteogenic differentiation-inducing culture (Fig. 6A, right panels) . Treatment of E18 cells with a specific inhibitor of Rho, C3 transferase (Aktories and Hall, 1989), completely blocked activation of Rho proteins under both myogenic and osteogenic differentiation-inducing conditions (Fig. 6B) . C3 transferase also prevented myogenic differentiation of E18 cells, although it did not inhibit ALP expression in them (Fig. 6C and D) . In contrast, C3 transferase did not affect calcification of E18 cells in the presence of bGP alone (Fig. 6E) . The results suggest that Rho functioning is essential for myogenic but not osteogenic terminal differentiation of E18 cells.
Modulation of Rho signaling alters the differentiation program of immortalized human myogenic progenitor cells
Discussion
We have shown that the human myogenic progenitor cell exhibits both osteoblast-and myoblast-specific properties both in vivo and in vitro. All human myogenic progenitor cell clones obtained in the present study retain dual cell lineagespecific properties. Thus, isolated human myogenic cells acquire their osteogenic properties cell-autonomously. The present study shows that at least one distinct subset of myogenic progenitor cells derived from human skeletal muscle preserves the dual lineage-specific properties although it remains to be determined whether all human myogenic progenitor cells retain both properties or not.
Previous studies of primary cultured mouse myogenic cell clones have identified multipotent myogenic progenitor cells that are able to give rise to myotubes, osteoblasts, and adipocytes in vitro (Wada et al., 2002) . Their osteogenic differentiation is completely dependent on stimulation with exogenous BMP2. In the present study, adult human myogenic progenitor cells were able to express bone ALP and osteocalcin, and form bone matrix spontaneously without exposure to any exogenous growth factor. FBS is assumed to contain BMPs at levels sufficient to induce differentiation in astrocytes (Kondo and Raff, 2004) . Previous studies suggest that BMPs prevent myogenesis of myogenic progenitor cells and also irreversibly induce osteogenesis (Wada et al., 2002) . However, human myogenic progenitor cells preserve muscle differentiation potential even though they already express an early osteogenic differentiation marker, ALP. In addition, the osteoblast-specific genes are down-regulated during terminal muscle differentiation. Myogenin is a possible candidate that suppresses Runx2 expression and other osteoblastic characteristics, as occurs in mouse myogenic cells (Wada et al., 2002) . Therefore, it is unlikely that the osteogenic properties of human myogenic progenitor cells are induced by exogenous BMPs, such as those derived from FBS, even if these cells are hypersensitive to BMPs.
The human myogenic progenitor cells analyzed here express BMP4 in a cell-autonomous way. However, it is unlikely that autocrined BMP4 is of importance to maintaining ALP expression of human myogenic progenitor cells because even an excess of noggin does not reduce expression levels of ALP. Nonetheless, we cannot exclude the possibility that autocrined BMP4 is involved in triggering, but not in maintaining, ALP expression in human myogenic cells. If that is indeed the case, the mode of BMP4 action should be quite different from those that have been shown in previous works. It is conceivable that prolonged exposure to BMP4, (A) E18 cells were cultured for 4 or 6 days in growth medium or serum-containing medium supplemented (or not) with either bGP (10 mM) alone, bGP plus BMP2 (500 ng/ml), bGP plus bFGF (10 ng/ml), or BMP2 alone. The deposited calcium was then quantified. Data are expressed as micrograms of calcium per 35 mm culture dish and are means ± SD of values from three experiments. (B) E18 cells were cultured for 6 days under the conditions described in (A) and were then subjected to RT-PCR analysis of the expression of MyoD, MCK, Runx2, osteocalcin (Osc), and GAPDH genes. The number of amplification cycles for MyoD was determined to detect the low level expression of MyoD under growing conditions (lane 1) although it might be somewhat excess for the other samples (lanes 2-6). (C) E18 cells were cultured for 6 days in serum-containing medium in the absence (left panels) or presence of bGP alone (middle panels) or of both bGP and BMP2 (right panels). They were then subjected to immunofluorescence analysis with antibodies to MyoD (red) and to MHC (green) (lower panels); phase-contrast images of the same fields are shown in upper panels, respectively. Scale bars, 50 lm. (D) Hu5 and E18 cells were cultured in pmGM and then subjected to RT-PCR analysis of the expression of BMP2, BMP4, BMP7 and myostatin genes. (E) E18 cells were cultured in pmGM with or without noggin/Fc for up to 3 days and then subjected to staining for ALP activity with Fast Blue RR. A macroscopic view of duplicated samples in a 96-well plate is shown. even at very low concentrations, induces osteogenic properties in human myogenic progenitor cells. In addition, we should note a possibility that autocrined myostatin modulates BMP binding to the BMP type I receptor ACVR1/ALK2 (Rebbapragada et al., 2003) . Therefore, the physiological role of autocrined BMP4 on human myogenic progenitor cells should be determined.
Myogenic progenitor cells derived from adult muscle satellite cells are fundamentally tissue-specific progenitor cells that are tonically restricted to the muscle lineage by the local parenchymal environment. Our results, however, suggest that human myogenic progenitor cells used do not require specific phenotypic reprogramming for osteogenic terminal differentiation and can act as ''determined osteoprogenitor cells'' under certain circumstances. The osteoblastic properties of E18 cells are not acquired during immortalization in vitro because their parent primary Hu5 cells also underwent osteogenic terminal differentiation without exogenous growth factor exposure.
Recently, human muscle pericytes expressing ALP have been shown to retain the capacity to regenerate skeletal muscle (Dellavalle et al., 2007) . In contrast to Hu5 cells, pericytederived myogenic cells express myogenic markers only in differentiated myotubes. Therefore, pericyte-derived myogenic cells may be distinct from myogenic progenitor cells used here. Nonetheless, we cannot exclude a possibility that both pericyte-derived myogenic cells and Hu5 cells belong to the same cell lineage because a minor subset of pericyte-derived myogenic cells contributes to the resident satellite cell pool (Dellavalle et al., 2007) .
Fibrodysplasia ossificans progressiva (FOP; OMIM 135100) is a heritable disorder characterized by progressive ossification of skeletal muscles (Kocyigit et al., 2001; Mahboubi et al., 2001) . The osteoprogenitor cells responsible for ectopic bone formation have not been identified in muscle of individuals with FOP. Previously, candidates for osteoprogenitor cells expressing smooth muscle markers and Runx2 were identified in the muscle of FOP patients (Hegyi et al., 2003; Levy et al., 2001 ), but their ability to form ectopic bone remains unknown. We have now shown that human myogenic progenitor cells form bone matrix in vitro. We therefore propose that myogenic progenitor cells are responsible for the ectopic ossification observed in human skeletal muscle. Previous studies have proposed that BMP2/4 or their antagonist noggin is responsible for the symptoms of FOP. However, dysfunction of BMPs and noggin in individuals with FOP remains to be elucidated (Cohen, 2002; Warman, 2002; Xu et al., 2000) . The involvement of BMPs in ectopic bone formation in skeletal muscle has not been shown in human disorders. Our finding that human myogenic progenitor cells do not require inductive agents to express osteogenic phenotypes has significant implications for ectopic bone formation in human skeletal muscle. FOP is thus a candidate for a disease caused by multipotent muscle progenitor cells that are misled down a heterotopic osteogenic differentiation pathway. Recently, a mutation in the BMP type I receptor ACVR1 was found in individuals with FOP, although how the mutation in ACVR1 perturbs BMP signaling is unknown (Shore et al., 2006) . It should be determined whether the mutation in ACVR1 switches the fate of human myogenic progenitor cells. The E18 cells established in the present study would contribute to further study on the function of mutated ACVR1 in human myogenic cells.
We previously proposed a ''stock options'' model for the generation of different fates from multipotent muscle stem cells (Wada et al., 2002) . This model proposes that stem cells can be activated and then induced to express multiple determination genes and thereby give rise to multipotent progenitor cells (multiblasts). Multiblast is defined as a multipotent progenitor cell derived from dormant muscle satellite cell. Multiblasts proliferate and increase in number during early Fig. 6 -Involvement of Rho signaling in the regulation of myogenensis but not osteogenesis of human myogenic progenitor cell E18. (A) E18 cells were cultured for up to 6 days in pmDM (left panels) or medium containing 10% FBS and 10 mM bGP (osteogenesis-inducing medium) (right panels). Cellular proteins were extracted and then activated Rho protein was affinity-purified. Twenty micrograms of total cellular proteins (upper panels) and purified activated Rho from 300 lg of the cell lysate (lower panels) were subjected to immunoblotting analysis with antibodies against Rho. This experiments is representative of three independent experiments. (B) E18 cells were cultured for 6 days in pmDM (left panels) or osteogenesis-inducing medium (right panels) in the absence (À) or presence (+) of 40 lg/ml C3 transferase. Levels of total and activated Rho proteins were determined as in (A). (C and D) E18 cells were cultured for 6 days in pmDM in the absence (C) or presence (D) of 40 lg/ml C3 transferase. Expressions of ALP activity (blue) and MHC (brown) were determined as described in Section 4. Scale bars, 50 lm. (E) E18 cells were cultured for 6 days in growth medium (growth), or osteogenesisinducing medium in the absence (À) or presence (+) of C3 transferase (40 lg/ml). The deposited calcium was then quantified. Data are expressed as micrograms of calcium per 35 mm culture dish and are means ± SD of values from nine experiments.
period of muscle regeneration. Depending on the differentiation-inducing conditions, determination genes or proteins not relevant to the induced terminal differentiation pathway are then down-regulated or functionally inactivated (Fig. 7A ). In addition, we assume that a minor subset of multiblasts contributes to the resident satellite cell pool. The present study indicates that human myogenic progenitor cells expressing multiple determination genes select an option for the terminal differentiation pathway according to this model. However, in contrast to mouse myogenic progenitor cells, human myogenic progenitor cells used here have the ability to undergo osteogenic differentiation without exogenous BMPs.
BMP2 has previously been shown to stimulate the expression of Runx2 (Lee et al., 2000; Takazawa et al., 2000) , which in turn induces the expression of osteogenic lineage-specific genes, including those for osteocalcin. However, our results indicate that BMP2 suppressed the transactivation of osteocalcin gene by Runx2 in confluent human myogenic cells expressing bone ALP. Although osteocalcin is a late marker of osteogenesis induced by Runx2 (Xiao et al., 1999) , it functions as an inhibitor of ossification (Ducy et al., 1996) . In addition, Runx2 inhibits osteogenic differentiation at a late stage (Liu et al., 2001) . We therefore propose that BMP2 inhibits the expression of osteocalcin gene by inactivating Runx2, resulting in enhancement of ossification. BMP2 may therefore activate Runx2 gene expression at an early stage of osteogenesis and subsequently inactivate Runx2 function at a late stage. A similar biphasic effect of BMP2 on osteocalcin gene expression was also apparent in mouse myogenic cells (Fig. S2 online) .
Rho family GTPases have been shown to be involved in the regulation of terminal differentiation in muscle (Bryan et al., 2005; Carnac et al., 1998; Gallo et al., 1999; Meriane et al., 2000; Takano et al., 1998) . In addition, Rho GTPase signaling regulates a switch in both the adipogenesis-myogenesis decision of embryonic mouse mesenchymal precursors (Sordella et al., 2003) and the adipogenesis-osteogenesis decision of human mesenchymal stem cells (McBeath et al., 2004) . C3 transferase inhibits myogenic but not osteogenic differentiation of human myogenic progenitor cells. Therefore, Rho GTPase signaling might be involved in a myogenesis-osteogenesis switch of human myogenic progenitor cells. Human myogenic progenitor cells preferentially undergo myogenic differentiation both in vivo and in vitro. However, accidental inactivation of a Rho signaling pathway would turn multipotent human myogenic progenitor cells into osteoprogenitors that have lost the ability to undergo myogenic differentiation (Fig. 7B) .
DMD is an X-linked human disease caused by dystrophin deficiency (Bonilla et al., 1988; Hoffman et al., 1987) . The mdx mouse, which harbors a mutated dystrophin gene, serves as an animal model of DMD (Ryder-Cook et al., 1988; Sicinski et al., 1989) . However, unlike in humans with DMD, regeneration overcomes the inherent muscle degeneration in the mdx mouse. Dystrophin deficiency thus causes progressive muscular dystrophy in a human-specific manner. Progressive ossification in FOP patients is also likely to be triggered in a human-specific manner, given that human myogenic cells retain species-specific properties (Fig. 7A) . To understand the mechanisms that cause human muscle diseases, the features of human myogenic progenitor cells must be elucidated. Taken together, the immortalized human myogenic cell lines established in the present study should provide a means with which to characterize further the human-specific properties of myogenic progenitor cells that might be critical for symptoms of human muscle diseases, including DMD and FOP. 
4.
Materials and methods
Cell culture
The human myogenic cell clone Hu5 was isolated from normal subcutaneous muscle tissue (Wada et al., 2002; Hashimoto et al., 2006) . Hu5 and its derivatives were maintained at 37°C under 10% CO 2 in dishes coated with type I collagen (Sumilon, Tokyo, Japan) and containing primary cultured myocyte growth medium (pmGM), consisting of Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% fetal bovine serum (FBS), 2% Ultroser G (Biosepra, Cedex-Saint-Christophe, France), and glucose (4.5 mg/ml). The immortalized human myogenic cell clone E18 is available from RIKEN BioResorce Center (http:// www.brc.riken.go.jp).
For induction of myogenic differentiation, cells were cultured in primary cultured myocyte differentiation medium (pmDM) consisting of the chemically defined medium TIS (Hashimoto et al., 1995; Hashimoto et al., 1994) supplemented with 2% FBS. For induction of osteogenic terminal differentiation, cells were cultured in DMEM supplemented with 10% FBS, glucose (4.5 mg/ml), and the indicated combinations of 10 mM b-glycerophosphate (bGP) (Sigma, St. Louis, MO), recombinant human bone morphogenetic protein (BMP2) (500 ng/ml) (Strathman Biotech, Hamburg, Germany, or PeproTech EC, London, UK), and human basic fibroblast growth factor (bFGF) (10 ng/ml) (PeproTech EC). For inhibition of BMPs, 2 · 10 3 Ric10 cells per well were plated in type I collagen-coated 96-well plate and cultured in pmGM supplemented with recombinant mouse noggin fused to the Fc region of human immunoglobulin chimeric protein (noggin/Fc, 0.1-10 mg/ml) (719-NG; R&D Systems, Minneapolis, MN).
Detection of calcification and ALP activity
Paraformaldehyde-fixed cultured cells were stained with the calcium-specific dye Alizarin Red S (0.01%, Sigma) for 30 min. Calcium deposited by cells in a 35 mm dish was extracted with 0.5 M HCl and then measured with a calcium quantification kit (Sigma).
ALP activity in cells fixed with 4% paraformaldehyde was detected by incubation of the cells for 20 min in a solution containing 100 mM Tris-HCl (pH 8.0), 100 mM NaCl, 50 mM MgCl 2 , 0.01% naphthol AS-MX, and Fast Blue RR (0.5 mg/ml). Cell nuclei were visualized by staining with 2, 4-diamidino-2-phenylindole dihydrochloride n-hydrate (DAPI) (0.5 lg/ml, Sigma).
4.3.
Immunofluorescence and immunochemical analyses Cultured cells were grown on collagen-coated coverslips (Iwaki, Tokyo, Japan) for immunofluorescence or immunocytochemical analysis. Muscle biopsy specimens were obtained with informed consent from individuals at the Kanagawa Cancer Center Research Institute or the National Center of Neurology and Psychiatry; they were frozen and sectioned at a thickness of 6 or 8 lm with a cryostat. The sections and cultured cells were fixed with 4% paraformaldehyde for 10 min at room temperature or placed on ice, respectively, and were then incubated with primary antibodies. Primary antibodies included those to Runx2 (kindly provided by Y. Ito) (Zhang et al., 2000) , mouse MyoD (Novocastra, Newcastle, UK), sarcomeric MHC (Bader et al., 1982) (kindly provided by T. Endo and T. Masaki), Pax7 (Ericson et al., 1996) (DSHB, Iowa City, IA), bone-specific ALP (Lawson et al., 1985) (B4-78 and B4-50; DSHB or kindly provided by T. Kimlinger), laminin (Sigma), dystrophin (Sigma), nestin (Arimatsu et al., 1999) (kindly provided by Y. Arimatsu), or desmin (Progen, Heidelberg, Germany). Secondary antibodies included biotinylated or Cy3-labeled antibodies to mouse or rabbit immunoglobulin G and Cy5-labeled antibodies to mouse immunoglobulin G (Jackson ImmunoResearch Laboratory, Bar Harbor, ME). The biotinylated antibodies were detected with streptavidin-conjugated horseradish peroxidase, Cy3, or fluorescein isothiocyanate. The peroxidase reaction was performed with 3,3-diaminobenzidine (Sigma) or TrueBlue substrate (KPL, Gaithersburg, MD). The antibodies to Runx2 were detected with biotinylated antibodies to mouse immunoglobulin G and a TSA Direct kit (New England Nuclear, Boston, MA). Cell nuclei were stained with 2,4-diamidino-2-phenylindole dihydrochloride nhydrate (DAPI). Samples were visualized using an upright microscope (model BX50; Olympus, Tokyo, Japan) and a CCD camera (DP50; Olympus). Images were also acquired using a confocal microscope (LSM 5 PASCAL; Carl Zeiss, Oberkochen, Germany) and an upright microscope (Axioplan 2; Carl Zeiss) equipped with a 40x Plan-NEOFLUAR objective lens. Images were post processed using Adobe Photoshop (Adobe Systems, San Jose, CA).
RT-PCR
Total RNA was extracted from cultured cells with TRIzol-LS (Life Technologies, Rockville, MD), treated with RNase-free DNase (RQ-1; Promega, Madison, WI), and then reverse transcribed with the use of a Ready-To-Go You-Prime First-Strand Beads (Amersham Pharmacia Biotech, Buckinghamshire, UK) and random hexamers as primers. Targeted genes were amplified by PCR with the primers listed in Table 1 .
4.5.
Rho activation assay
The activation of Rho was monitored with an affinity purification assay (Ren et al., 1999) performed with the Rho Activation Assay Biochem Kit (Cytoskeleton, Denver, CO) using 300 lg of each cell lysate. Immunoblotting analysis was done as described previously (Hashimoto et al., 2004; Hashimoto and Ogashiwa, 1997; Hashimoto et al., 1995) . Immune complexes were detected with the use of chemiluminescence reagents (Amersham Pharmacia Biotech).
